US drug giant Eli Lilly, whose stock tumbled in August after it lost a key patent battle over its antidepressant Prozac, yesterday reported a 15 per cent rise in third-quarter net profit, led by sales of drugs for schizophrenia, cancer and osteoporosis.

The maker of osteoporosis drug Evista and diabetes medicines, said net income rose to $778.8 million matching expectations.